PROCEPT BioRobotics (PRCT) Misses Q4 EPS by 21c, Offers Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/23/2026
- Dow, S&P 500 fall, tech steadies to end rocky weekÂ
- Meta's capital-raising plans expose a major weakness in the AI boom
- Brent crude jumps to highest since April on Houthi-Saudi attacks, UAE oil spill
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
Tweet
Share
E-mailGet Alerts PRCT Hot Sheet
Join SI Premium – FREE
PROCEPT BioRobotics Corporation (NASDAQ: PRCT) reported Q4 EPS of ($0.53), $0.21 worse than the analyst estimate of ($0.32). Revenue for the quarter came in at $76.1 million versus the consensus estimate of $93.77 million.
GUIDANCE:
PROCEPT BioRobotics Corporation sees FY2026 revenue of $390-410 million, versus the consensus of $422 million.
For earnings history and earnings-related data on PROCEPT BioRobotics Corporation (PRCT) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Meta's Muse AI to counter China models with subscribers, not ads, Alexandr Wang says - Nikkei
- U.S. to remove 50% tariff on some Canadian products - WSJ
- Freedom Broker Downgrades Valero Energy (VLO) to Sell
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
